Private equity firm Carlyle Group is in exclusive discussions to purchase Baxter International’s kidney care spinoff, Vantive, in a deal valued at around $4bn including debt, according to reports by Reuters and the Wall Street Journal.
The report cites an unnamed source in revealing that the parties entered exclusive negotiations in late June, and an announcement over a deal could be made in the coming weeks.
Shares of Baxter International, based in Deerfield, Illinois, have risen by more than 4% since news of the potential deal broke.
In March, Baxter announced it was exploring the sale of its kidney care unit with select private equity investors. The decision came more than a year after Baxter revealed plans to separate the unit due to supply chain challenges and weak demand for dialysis operations. The company aims to complete the separation in the second half of the year.
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...